Literature DB >> 22811535

Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation.

Diana D Y Wong1, Ka-Tim Choy, Renee W Y Chan, Sin Fun Sia, Hsin-Ping Chiu, Peter P H Cheung, Michael C W Chan, J S Malik Peiris, Hui-Ling Yen.   

Abstract

Limited antiviral compounds are available for the control of influenza, and the emergence of resistant variants would further narrow the options for defense. The H275Y neuraminidase (NA) mutation, which confers resistance to oseltamivir carboxylate, has been identified among the seasonal H1N1 and 2009 pandemic influenza viruses; however, those H275Y resistant variants demonstrated distinct epidemiological outcomes in humans. Specifically, dominance of the H275Y variant over the oseltamivir-sensitive viruses was only reported for a seasonal H1N1 variant during 2008-2009. Here, we systematically analyze the effect of the H275Y NA mutation on viral fitness and transmissibility of A(H1N1)pdm09 and seasonal H1N1 influenza viruses. The NA genes from A(H1N1)pdm09 A/California/04/09 (CA04), seasonal H1N1 A/New Caledonia/20/1999 (NewCal), and A/Brisbane/59/2007 (Brisbane) were individually introduced into the genetic background of CA04. The H275Y mutation led to reduced NA enzyme activity, an increased K(m) for 3'-sialylactose or 6'-sialylactose, and decreased infectivity in mucin-secreting human airway epithelial cells compared to the oseltamivir-sensitive wild-type counterparts. Attenuated pathogenicity in both RG-CA04(NA-H275Y) and RG-CA04 × Brisbane(NA-H275Y) viruses was observed in ferrets compared to RG-CA04 virus, although the transmissibility was minimally affected. In parallel experiments using recombinant Brisbane viruses differing by hemagglutinin and NA, comparable direct contact and respiratory droplet transmissibilities were observed among RG-NewCal(HA,NA), RG-NewCal(HA,NA-H275Y), RG-Brisbane(HA,NA-H275Y), and RG-NewCal(HA) × Brisbane(NA-H275Y) viruses. Our results demonstrate that, despite the H275Y mutation leading to a minor reduction in viral fitness, the transmission potentials of three different antigenic strains carrying this mutation were comparable in the naïve ferret model.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22811535      PMCID: PMC3457312          DOI: 10.1128/JVI.00985-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  Update: influenza activity - United States, 2009-10 season.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-07-30       Impact factor: 17.586

2.  Permissive secondary mutations enable the evolution of influenza oseltamivir resistance.

Authors:  Jesse D Bloom; Lizhi Ian Gong; David Baltimore
Journal:  Science       Date:  2010-06-04       Impact factor: 47.728

3.  Adaptation of pandemic H1N1 influenza viruses in mice.

Authors:  Natalia A Ilyushina; Alexey M Khalenkov; Jon P Seiler; Heather L Forrest; Nicolai V Bovin; Henju Marjuki; Subrata Barman; Robert G Webster; Richard J Webby
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

4.  Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models.

Authors:  Christopher W Seibert; Michael Kaminski; Jennifer Philipp; Dennis Rubbenstroth; Randy A Albrecht; Folker Schwalm; Silke Stertz; Rafael A Medina; Georg Kochs; Adolfo García-Sastre; Peter Staeheli; Peter Palese
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

5.  Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model.

Authors:  Aeron C Hurt; Siti Sarah Nor'e; James M McCaw; Helen R Fryer; Jennifer Mosse; Angela R McLean; Ian G Barr
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

Review 6.  Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir.

Authors:  David Reddy
Journal:  J Antimicrob Chemother       Date:  2010-04       Impact factor: 5.790

7.  Variations in the hemagglutinin of the 2009 H1N1 pandemic virus: potential for strains with altered virulence phenotype?

Authors:  Jianqiang Ye; Erin M Sorrell; Yibin Cai; Hongxia Shao; Kemin Xu; Lindomar Pena; Danielle Hickman; Haichen Song; Matthew Angel; Rafael A Medina; Balaji Manicassamy; Adolfo Garcia-Sastre; Daniel R Perez
Journal:  PLoS Pathog       Date:  2010-10-14       Impact factor: 6.823

8.  Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets.

Authors:  Susu Duan; David A Boltz; Patrick Seiler; Jiang Li; Karoline Bragstad; Lars P Nielsen; Richard J Webby; Robert G Webster; Elena A Govorkova
Journal:  PLoS Pathog       Date:  2010-07-29       Impact factor: 6.823

9.  Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets.

Authors:  Marie-Eve Hamelin; Mariana Baz; Yacine Abed; Christian Couture; Philippe Joubert; Edith Beaulieu; Nathalie Bellerose; Martin Plante; Corey Mallett; Gregg Schumer; Gary P Kobinger; Guy Boivin
Journal:  PLoS Pathog       Date:  2010-07-22       Impact factor: 6.823

10.  Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses.

Authors:  Maki Kiso; Kyoko Shinya; Masayuki Shimojima; Ryo Takano; Kei Takahashi; Hiroaki Katsura; Satoshi Kakugawa; Mai Thi Quynh Le; Makoto Yamashita; Yousuke Furuta; Makoto Ozawa; Yoshihiro Kawaoka
Journal:  PLoS Pathog       Date:  2010-08-26       Impact factor: 6.823

View more
  19 in total

1.  Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.

Authors:  Kanyarat Ruangrung; Ornpreya Suptawiwat; Kittipong Maneechotesuwan; Chompunuch Boonarkart; Warunya Chakritbudsabong; Jirawatna Assawabhumi; Parvapan Bhattarakosol; Mongkol Uiprasertkul; Pilaipan Puthavathana; Witthawat Wiriyarat; Anan Jongkaewwattana; Prasert Auewarakul
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

2.  Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.

Authors:  Andrew J Burnham; Tatiana Baranovich; Bindumadhav M Marathe; Jianling Armstrong; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

3.  Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference.

Authors:  Jennifer L McKimm-Breschkin; Shibo Jiang; David S Hui; John H Beigel; Elena A Govorkova; Nelson Lee
Journal:  Antiviral Res       Date:  2017-11-21       Impact factor: 5.970

4.  Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets.

Authors:  Yacine Abed; Andrés Pizzorno; Xavier Bouhy; Chantal Rhéaume; Guy Boivin
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

Review 5.  Use of ex vivo and in vitro cultures of the human respiratory tract to study the tropism and host responses of highly pathogenic avian influenza A (H5N1) and other influenza viruses.

Authors:  Renee W Y Chan; Michael C W Chan; John M Nicholls; J S Malik Peiris
Journal:  Virus Res       Date:  2013-05-15       Impact factor: 3.303

6.  Drug Repurposing Identifies Inhibitors of Oseltamivir-Resistant Influenza Viruses.

Authors:  Ju Bao; Bindumadhav Marathe; Elena A Govorkova; Jie J Zheng
Journal:  Angew Chem Int Ed Engl       Date:  2016-02-02       Impact factor: 15.336

7.  Pandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model.

Authors:  Michael M Kaminski; Annette Ohnemus; Peter Staeheli; Dennis Rubbenstroth
Journal:  J Virol       Date:  2012-11-28       Impact factor: 5.103

8.  Matrix Protein 2 Extracellular Domain-Specific Monoclonal Antibodies Are an Effective and Potentially Universal Treatment for Influenza A.

Authors:  Lynn Bimler; Sydney L Ronzulli; Amber Y Song; Scott K Johnson; Cheryl A Jones; Teha Kim; Duy T Le; S Mark Tompkins; Silke Paust
Journal:  J Virol       Date:  2020-12-02       Impact factor: 6.549

9.  Impact of the H275Y and I223V Mutations in the Neuraminidase of the 2009 Pandemic Influenza Virus In Vitro and Evaluating Experimental Reproducibility.

Authors:  Eric G Paradis; Lady Tatiana Pinilla; Benjamin P Holder; Yacine Abed; Guy Boivin; Catherine A A Beauchemin
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

10.  A(H1N1)pdm09 Influenza Viruses Replicating in Ferret Upper or Lower Respiratory Tract Differed in Onward Transmission Potential by Air.

Authors:  Chenyi Xie; Wen Su; Sin Fun Sia; Ka-Tim Choy; Steven Morrell; Jie Zhou; Malik Peiris; Jesse D Bloom; Hui-Ling Yen
Journal:  J Infect Dis       Date:  2022-01-05       Impact factor: 7.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.